Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARMP

Armata Pharmaceuticals Inc

Dec 13 • 04:00PM ET

2.19

Dollar change +0.09
Percentage change 4.37	%

Healthcare • Biotechnology • USA • AMEX

Peers: SRPT SAGE OCUL GALT TGTX PTCT BCRX TXMD CRBP MNOV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.64	Insider Own	70.28%	Shs Outstand	36.18M	Perf Week	0.08%
Market Cap	79.30M	Forward P/E	-	EPS next Y	-1.70	Insider Trans	0.00%	Shs Float	10.76M	Perf Month	-19.42%
Income	-41.36M	PEG	-	EPS next Q	-0.35	Inst Own	3.82%	Short Float	0.02%	Perf Quarter	-3.66%
Sales	5.47M	P/S	14.50	EPS this Y	50.26%	Inst Trans	-1.50%	Short Ratio	0.35	Perf Half Y	-23.63%
Book/sh	-1.41	P/B	-	EPS next Y	-78.95%	ROA	-39.21%	Short Interest	0.00M	Perf Year	-19.12%
Cash/sh	0.47	P/C	4.63	EPS next 5Y	-	ROE	-3439.35%	52W Range	1.98 - 4.48	Perf YTD	-32.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	47.98%	ROI	-	52W High	-51.08%	Beta	0.82
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	89.79%	Gross Margin	77.59%	52W Low	10.70%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	30.59%	Oper. Margin	-758.68%	RSI (14)	46.98	Volatility	7.28% 6.40%
Employees	66	Debt/Eq	-	Sales Y/Y TTM	34.92%	Profit Margin	-756.59%	Recom	1.00	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	82.46%	Payout	-	Rel Volume	0.32	Prev Close	2.10
Sales Surprise	230.33%	EPS Surprise	46.43%	Sales Q/Q	142.69%	Earnings	Nov 13 AMC	Avg Volume	7.66K	Price	2.19
SMA20	-0.56%	SMA50	-4.88%	SMA200	-19.10%	Trades		Volume	2,459	Change	4.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-19-19	Initiated	Ladenburg Thalmann	Buy	$9

Nov-19-24 07:00AM	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting (PR Newswire) -11.61%
Nov-13-24 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update (PR Newswire)
Nov-12-24 07:00AM	Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia (PR Newswire) +22.22%
Oct-30-24 07:00AM	Armata Pharmaceuticals Announces Structural Biology Publication (PR Newswire)
Sep-12-24 12:00PM	Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:30AM	Loading…
Sep-05-24 07:30AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-26-24 07:30AM	Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium (PR Newswire)
Aug-15-24 04:45PM	Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer (PR Newswire) -6.97%
Aug-13-24 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update (PR Newswire) +6.27% -10.70%
Jul-30-24 07:00AM	Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 (PR Newswire)
Jul-11-24 07:00AM	Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire) +11.94%
Jul-10-24 04:05PM	Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 (PR Newswire) +5.10%
May-07-24 04:01PM	Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update (PR Newswire) +13.94%
Mar-21-24 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update (PR Newswire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire) -8.50%
07:00AM	Loading…
Feb-21-24 07:00AM	Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit (PR Newswire)
Nov-14-23 04:00PM	Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update (PR Newswire) +8.94% -19.78%
Oct-30-23 08:00AM	Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference (PR Newswire) +10.19%
Oct-19-23 08:00AM	Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 (PR Newswire)
Sep-26-23 08:00AM	Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus (PR Newswire)
Sep-21-23 07:00AM	Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (PR Newswire)
Aug-17-23 09:55AM	Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-14-23 07:00AM	Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update (PR Newswire)
Jul-11-23 08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
May-31-23 08:00AM	Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy (PR Newswire)
May-11-23 04:05PM	Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update (PR Newswire)
Mar-16-23 04:10PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update (PR Newswire) +5.42% +8.57%
Mar-06-23 06:00AM	Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis (PR Newswire) +10.87%
Jan-10-23 04:05PM	Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC (PR Newswire) +25.38%
Dec-22-22 08:00AM	Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire) -6.99%
09:55AM	Loading…
Dec-08-22 09:55AM	Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-28-22 09:35AM	After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP) (Zacks)
08:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (PR Newswire)
Nov-15-22 09:55AM	Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing (Zacks) -9.66%
Nov-09-22 04:15PM	Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update (PR Newswire) -8.23%
Aug-11-22 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update (PR Newswire)
Aug-01-22 08:00AM	Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections (PR Newswire)
May-23-22 08:00AM	Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus (PR Newswire)
May-12-22 04:17PM	Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update (PR Newswire) -5.00%
Mar-31-22 04:05PM	Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva (PR Newswire) -8.60%
Mar-22-22 10:00AM	Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High? (Zacks) +5.17%
Mar-17-22 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update (PR Newswire) +5.37% +17.74%
Mar-09-22 05:28PM	Armata Pharmaceuticals to move headquarters to Playa Vista (American City Business Journals)
Feb-22-22 08:00AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis (PR Newswire)
Feb-17-22 08:00AM	Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences (PR Newswire)
Feb-09-22 04:16PM	Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development (PR Newswire)
Jan-06-22 08:50AM	Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why (Zacks) +7.12%
Jan-05-22 08:00AM	Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs (PR Newswire) +6.12%
Nov-29-21 10:00AM	Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade (Zacks) -17.62%
Nov-18-21 08:00AM	Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs (PR Newswire)
Nov-17-21 12:00PM	What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock (Zacks) +8.07%
Nov-10-21 04:05PM	Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update (PR Newswire) -6.61%
Nov-04-21 03:01PM	Armata Pharmaceuticals, Inc. (ARMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress (PR Newswire)
Nov-02-21 08:00AM	Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility (PR Newswire)
Oct-28-21 06:41PM	Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals (PR Newswire) +6.67%
Sep-08-21 08:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-12-21 04:05PM	Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update (PR Newswire)
Aug-05-21 03:00PM	Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know (Zacks)
Aug-02-21 07:30AM	Armata Pharmaceuticals Announces Chief Executive Officer Transition (PR Newswire)
Jul-07-21 07:30AM	Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (PR Newswire)
May-13-21 04:05PM	Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update (PR Newswire)
10:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire)
Mar-18-21 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update (PR Newswire)
Mar-17-21 04:01PM	Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva (PR Newswire)
Mar-16-21 11:01AM	Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference (PR Newswire)
Jan-27-21 07:01AM	Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs (PR Newswire)
Dec-09-20 07:30AM	Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors (PR Newswire)
Nov-16-20 11:10PM	Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts (Simply Wall St.) -13.97%
Nov-15-20 07:17AM	Earnings Beat: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts (Simply Wall St.)
Nov-12-20 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update (PR Newswire) +7.95% -7.36%
Oct-29-20 07:30AM	Armata Pharmaceuticals Issues Letter to Shareholders (PR Newswire) +7.00%
Oct-26-20 07:30AM	Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development (PR Newswire)
Oct-15-20 07:30AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections (PR Newswire) +8.86%
Sep-29-20 07:30AM	Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress (PR Newswire)
Sep-11-20 07:30AM	Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences (PR Newswire)
Aug-13-20 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update (PR Newswire)
Jun-30-20 06:05AM	Here's Why We're Watching Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Situation (Simply Wall St.)
Jun-17-20 07:30AM	Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections (PR Newswire) +10.33%
May-14-20 04:05PM	Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update (PR Newswire)
Apr-28-20 08:00AM	Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector (PR Newswire)
Mar-30-20 07:30AM	Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. (PR Newswire)
Mar-19-20 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update (PR Newswire) -6.46%
Mar-18-20 08:00AM	Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation (PR Newswire) +10.94%
Feb-13-20 08:00AM	Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc. (PR Newswire)
Jan-29-20 08:04AM	Company News For Jan 29, 2020 (Zacks) -26.80%
Jan-28-20 07:00AM	Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs (PR Newswire) +73.84%
Nov-12-19 04:05PM	Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update (PR Newswire) -9.69%
Oct-31-19 10:52AM	We're Keeping An Eye On Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Rate (Simply Wall St.)
07:05AM	Armata Pharmaceuticals Issues Letter to Shareholders (PR Newswire)
Oct-21-19 07:05AM	Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive (PR Newswire)
Oct-16-19 07:05AM	Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director (PR Newswire)
Oct-10-19 04:05PM	Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D. (PR Newswire)
Sep-19-19 07:05AM	Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference (PR Newswire)
Sep-12-19 09:00AM	Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa (PR Newswire)
Aug-14-19 04:05PM	Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update (PR Newswire) -6.09%
Aug-02-19 03:27PM	How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own? (Simply Wall St.)
Aug-01-19 10:30AM	Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference (PR Newswire)
Jun-18-19 07:01AM	Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York (PR Newswire)
Jun-03-19 07:01AM	Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada (PR Newswire) -5.96%

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARMP

Armata Pharmaceuticals Inc

Upgrade your FINVIZ experience